Depression is an established risk factor for the development of coronary heart disease (CHD) in healthy patients [1, 2] and for adverse cardiovascular outcomes in patients with existing CHD [3, 4] . A deeper biological understanding of the causes of depression in patients with cardiovascular disease is critical to improve the prevention and treatment of both conditions [5, 6] . Dietary factors resulting in lower levels of -3 fatty acids not only increase CHD risk [7, 8] , but may also be involved in the pathophysiology of depression. Lower levels of -3 fatty acids, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been associated with depression in both healthy adult populations [9, 10] and in patients with acute coronary syndrome [11, 12] . It is unknown whether low -3 fatty acid levels are associated with depression in patients with stable CHD.
We measured red blood cell levels of two -3 fatty acids, EPA and DHA, and assessed depressive symptoms in a cross-sectional study of 987 adults with CHD. The Heart and Soul Study is a prospective cohort study examining psychosocial factors and health outcomes in patients with established CHD. Detailed methods have previously been described [13] . Between 2000 and 2002, a total of 1,024 San Francisco area residents enrolled and completed a baseline study visit. Subjects without frozen blood samples (n = 37) were excluded, resulting in a final sample size of 987. -3 fatty acids were blindly measured in fasting venous blood samples using capillary gas chromatography to measure the fatty acid composition of red blood cell membranes. Red blood cell levels of EPA and DHA are presented as a percentage composition of total fatty acid methyl esters. We assessed current depression using the Our study extends this existing literature by finding a strong association between low -3 fatty acids and depression in outpatients with stable CHD, a population distinct from sicker, hospitalized patients with acute coronary syndrome. In addition, we examined the role of several important potential confounders and measured erythrocyte membrane levels of fatty acids rather than using less accurate serum measurements or dietary questionnaires. However, the cross-sectional nature of our study precluded us from making any definitive comments on causality. Additionally, our cohort participants were mostly older, urban men and thus are not entirely reflective of the general population.
In an effort to improve current cardiovascular prevention strategies, some have suggested providing -3 fatty acid supplements to CHD patients with a diagnosis of depression [11] . Because depression increases both cardiovascular risk and cardiovascular disease-related morbidity and mortality [1] [2] [3] [4] [19] [20] [21] , a potential reduction in the incidence of depression in patients with CHD by -3 fatty acid supplementation could lead to less adverse cardiac outcomes. However, given that differences in SES appeared to explain the association between -3 fatty acids and depression in our study, we are less confident that treatment with -3 fatty acids can improve depressive symptoms in patients with stable CHD. Since SES is an important risk factor for both poor diet and depression [22] , it is possible that -3 fatty acid levels are not associated with depressive symptoms independent of SES [23] . To better understand the potential efficacy of -3 fatty acid supplementation for improving depressive symptoms in patients with CHD, future studies should carefully consider the role of SES in this association.
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